| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
195,811,000 |
| Market
Cap: |
1.32(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.08 - $6.74 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing and developing plasma-derived biologics for the treatment of immunodeficient patients at risk for infectious diseases. Co.'s products include: BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV (Immune Globulin Intravenous, Human – slra 10% Liquid), an IVIG product indicated for the treatment of PI; and Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing HBsAg and other listed exposures to Hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
155,000 |
191,958 |
| Total Buy Value |
$0 |
$0 |
$579,644 |
$685,344 |
| Total People Bought |
0 |
0 |
2 |
4 |
| Total Buy Transactions |
0 |
0 |
2 |
5 |
| Total Shares Sold |
1,500,000 |
1,500,000 |
4,083,538 |
4,083,538 |
| Total Sell Value |
$9,143,159 |
$9,143,159 |
$19,811,348 |
$19,811,348 |
| Total People Sold |
1 |
1 |
4 |
4 |
| Total Sell Transactions |
5 |
5 |
11 |
11 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lenz Brian |
EVP, CFO |
• – – |
2019-05-17 |
4 |
B |
$4.00 |
$20,000 |
D/D |
5,000 |
25,000 |
2.74 |
- |
|
| Mond James |
EVP, CSO and CMO |
• – – |
2019-05-17 |
4 |
B |
$4.00 |
$18,000 |
D/D |
4,500 |
17,889 |
2.74 |
- |
|
| Grossman Adam S |
President and CEO |
• • – |
2019-05-17 |
4 |
B |
$4.00 |
$100,000 |
I/I |
25,000 |
821,301 |
2.66 |
- |
|
| Grossman Adam S |
President and CEO |
• • – |
2019-05-17 |
4 |
B |
$4.00 |
$20,000 |
D/D |
5,000 |
37,527 |
2.81 |
- |
|
| Guiheen Lawrence P. |
Director |
– • – |
2019-05-17 |
4 |
B |
$4.00 |
$100,000 |
D/D |
25,000 |
50,000 |
2.39 |
- |
|
| Guiheen Lawrence P. |
Director |
– • – |
2018-06-08 |
4 |
B |
$4.78 |
$95,600 |
D/D |
20,000 |
25,000 |
2.39 |
- |
|
| Richman Eric I |
Director |
– • – |
2018-06-08 |
4 |
B |
$4.78 |
$24,999 |
D/D |
5,230 |
36,530 |
2.39 |
- |
|
| Grossman Adam S |
President and CEO |
• • – |
2018-06-08 |
4 |
B |
$4.78 |
$249,999 |
I/I |
52,301 |
796,301 |
2.66 |
- |
|
| Grossman Adam S |
President and CEO |
• • – |
2018-06-08 |
4 |
B |
$4.78 |
$100,002 |
D/D |
20,921 |
32,527 |
2.81 |
- |
|
| Grossman Jerrold B |
Director |
– • – |
2018-06-08 |
4 |
B |
$4.78 |
$150,001 |
I/I |
31,381 |
31,381 |
2.1 |
- |
|
| Grossman Jerrold B |
Director |
– • – |
2018-06-08 |
4 |
B |
$4.78 |
$100,002 |
D/D |
20,921 |
98,007 |
2.39 |
- |
|
| Lenz Brian |
VP, CFO |
• – – |
2018-06-08 |
4 |
B |
$4.78 |
$23,900 |
D/D |
5,000 |
20,000 |
2.74 |
- |
|
| Biotest Divestiture Trust |
10% Owner |
– – • |
2018-05-14 |
4 |
S |
$0.00 |
$0 |
I/I |
(8,591,160) |
0 |
|
- |
|
| Biotest Pharmaceuticals Corp |
10% Owner |
– – • |
2018-05-14 |
4 |
S |
$0.00 |
$0 |
I/I |
(8,591,160) |
0 |
|
- |
|
| Biotest Pharmaceuticals Corp |
Director |
– • • |
2017-11-09 |
4 |
B |
$2.15 |
$12,500,001 |
I/I |
5,813,954 |
10,109,534 |
2.25 |
- |
|
| Richman Eric I |
Director |
– • – |
2017-11-09 |
4 |
B |
$2.15 |
$53,750 |
D/D |
25,000 |
31,300 |
2.39 |
- |
|
| Mond James |
EVP, CSO and CMO |
• – – |
2017-11-09 |
4 |
B |
$2.15 |
$21,500 |
D/D |
10,000 |
13,389 |
2.74 |
- |
|
| Grossman Adam S |
President and CEO |
• • – |
2017-11-09 |
4 |
B |
$2.15 |
$1,042,750 |
I/I |
485,000 |
744,000 |
2.66 |
- |
|
| Lenz Brian |
VP, CFO |
• – – |
2017-11-09 |
4 |
B |
$2.15 |
$13,975 |
D/D |
6,500 |
15,000 |
2.74 |
- |
|
| Richman Eric I |
Director |
– • – |
2017-07-13 |
4 |
OE |
$2.68 |
$7,504 |
D/D |
2,800 |
6,300 |
|
- |
|
| Grossman Adam S |
President and CEO |
• • – |
2017-07-13 |
4 |
D |
$3.30 |
$112,616 |
D/D |
(34,126) |
11,606 |
|
- |
|
| Grossman Adam S |
President and CEO |
• • – |
2017-07-13 |
4 |
OE |
$2.68 |
$112,616 |
D/D |
42,021 |
45,732 |
|
- |
|
| Grossman Jerrold B |
Director |
– • – |
2017-07-13 |
4 |
D |
$3.30 |
$129,136 |
D/D |
(39,132) |
77,086 |
|
- |
|
| Grossman Jerrold B |
Director |
– • – |
2017-07-13 |
4 |
OE |
$2.68 |
$129,136 |
D/D |
48,185 |
116,218 |
|
- |
|
| Biotest Pharmaceuticals Corp |
10% Owner |
– – • |
2017-06-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,295,580 |
|
- |
|
222 Records found
|
|
Page 6 of 9 |
|
|
0.07 (1.05%) 
